1e:T496,Chemodynamic therapy (CDT) utilizes iron-initiated Fenton chemistry to destroy tumor cells by converting endogenous H₂ O₂ into the highly toxic hydroxyl radical (^. OH). There is a paucity of Fenton-like metal-based CDT agents. Intracellular glutathione (GSH) with ^. OH scavenging ability greatly reduces CDT efficacy. A self-reinforcing CDT nanoagent based on MnO₂ is reported that has both Fenton-like Mn²⁺ delivery and GSH depletion properties. In the presence of HCO₃^- , which is abundant in the physiological medium, Mn²⁺ exerts Fenton-like activity to generate ^. OH from H₂ O₂ . Upon uptake of MnO₂ -coated mesoporous silica nanoparticles (MS@MnO₂ NPs) by cancer cells, the MnO₂ shell undergoes a redox reaction with GSH to form glutathione disulfide and Mn²⁺ , resulting in GSH depletion-enhanced CDT. This, together with the GSH-activated MRI contrast effect and dissociation of MnO₂ , allows MS@MnO₂ NPs to achieve MRI-monitored chemo-chemodynamic combination therapy.1f:T476,Cell-derived nanoparticles have been garnering increased attention due to their ability to mimic many of the natural properties displayed by their source cells. This top-down engineering approach can be applied toward the development of novel therapeutic strategies owing to the unique interactions enabled through the retention of complex antigenic information. Herein, we report on the biological functionalization of polymeric nanoparticles with a layer of membrane coating derived from cancer cells. The resulting core-shell nanostructures, which carry the full array of cancer cell membrane antigens, offer a robust platform with applicability toward multiple modes of anticancer therapy. We demonstrate that by coupling the particles with an immunological adjuvant, the resulting formulation can be used to promote a tumor-specific immune response for use in vaccine applications. Moreover, we show that by taking advantage of the inherent homotypic binding phenomenon frequently observed among tumor cells the membrane functionalization allows for a unique cancer targeting strategy that can be utilized for drug delivery applications.20:T5c1,

	Year	Citations

References